Hospital-built environment colonization by healthcare-associated infections-related bacteria (HAIrB) and the interaction with their occupants have been studied to support more effective tools for HAI control. To investigate HAIrB dynamics and antimicrobial resistance (AMR) profile we carried out a 6-month surveillance program in a developing country public hospital, targeting patients, hospital environment, and healthcare workers, using culture-dependent and culture-independent 16S rRNA gene sequencing methods. The bacterial abundance in both approaches shows that the HAIrB group has important representativeness, with the taxa Enterobacteriaceae, Pseudomonas, Staphylococcus, E. coli, and A. baumannii widely dispersed and abundant over the time at the five different hospital units included in the survey. We observed a high abundance of HAIrB in the patient rectum, hands, and nasal sites. In the healthcare workers, the HAIrB distribution was similar for the hands, protective clothing, and mobile phones. In the hospital environment, the healthcare workers resting areas, bathrooms, and bed equipment presented a wide distribution of HAIrB and AMR, being classified as contamination hotspots. AMR is highest in patients, followed by the environment and healthcare workers. The most frequently detected beta-lactamases genes were, blaSHV–like, blaOXA–23–like, blaOXA–51–like, blaKPC–like, blaCTX–M–1, blaCTX–M–8, and blaCTX–M–9 groups. Our results demonstrate that there is a wide spread of antimicrobial resistance due to HAIrB in the hospital environment, circulating among patients and healthcare workers. The contamination hotspots identified proved to be constant over time. In the fight for patient safety, these findings can reorient practices and help to set up new guidelines for HAI control.
Avaliação dos indicadores de qualidade de laboratórios de citopatologia cervical RESUMONeste trabalho foi avaliado o desempenho dos 13 laboratórios que realizaram o exame citopatológico para o SUS no Paraná, por meio de seis indicadores do monitoramento interno da qualidade (MIQ). Foi realizado estudo retrospectivo, baseado nos dados obtidos no programa do Ministério da Saúde, SISCOLO/CNES, dos laboratórios que efetuaram acima de 1.500 exames de Papanicolaou/ano, de janeiro de 2008 a dezembro de 2012. A avaliação da qualidade dos laboratórios foi feita pela análise do índice de positividade (IP), percentuais de exames compatíveis com ASC entre os exames satisfatórios, ASC entre os exames alterados, exames compatíveis com HSIL, exames insatisfatórios e razão ASC/SIL. Dos laboratórios avaliados, apenas um apresentou produtividade maior que 15 mil exames/ano conforme recomendação da QualiCito, e correspondeu a 82,9 % dos exames realizados no estado. O IP mostrou que 46,1 % dos laboratórios apresentaram resultado muito baixo, 38,5 % baixo, apenas 18,1 % dentro da faixa esperada. Com relação ao percentual de HSIL, 23,1 % dos laboratórios apresentaram percentual igual ou superior a 0,4 %. Portanto, os resultados deste estudo mostraram que os indicadores de qualidade do MIQ, dos laboratórios que realizaram exame citopatológico para o SUS, estão abaixo dos parâmetros recomendado pelo Ministério da Saúde. Palavras-chave. controle de qualidade, citologia, colo do útero. ABSTRACTThis study aimed at evaluating the profile of 13 laboratories that perform the Pap smear for the Public Healthcare System in Paraná State, Brazil, through six internal quality monitoring indicators (MIQ). This retrospective study was based on the data obtained from the Ministry of Health Program, SISCOLO/ CNES, including laboratories performing over 1500 Pap tests/year, from January 2008 to April 2013. The quality assessment of laboratories was performed by analyzing the positivity rate (PR), the percentage of tests compatible with ASC among satisfactory examinations, the ASC among abnormal tests, the tests compatible with HSIL, the unsatisfactory rate and the ASC/SIL ratio. Of analyzed laboratories, only one demonstrated productivity higher than 15.000 tests/year as recommended by QualiCito, and these corresponded to 82.9 % of tests performed in the State. The PR was very low in 46.1 % of laboratories and low in 38.5 %; 18.1 % of laboratories only were within the expected range. The percentage of HSIL was equal to or greater than 0.4 % in 23.1 % of laboratories. Therefore, this study showed that the quality indicators of MIQ of the laboratories performing the cervical cancer screening are below the parameters recommended by the Ministry of Health.
Plasmid-mediated polymyxin resistance has become a global health concern, not only because its dissemination has occurred drastically but also because it has begun to be reported in multidrug-resistant (MDR) pathogens. We hereby report microbiological and genomic characteristics of two mcr-1.1-positive polymyxin-resistant Escherichia coli isolates identified for the first time in community patients, in Santa Catarina, Southern Brazil. E. coli strains belonging to ST206 and ST354 and the resistome analysis revealed the presence of clinically important genes responsible for MDR profile. Interestingly, in both polymyxin-resistant E. coli strains, mcr-1.1 genes were carried by IncX4 plasmids, responsible for the worldwide dissemination of mcr-type genes. In this regard, plasmid backbones were almost identical to the first IncX4 plasmid reported in Brazil and sharing more than 99.9% identity to IncX4 plasmids from China, also lacking the ISApl1 insertion sequence upstream of mcr-1. In conclusion, these data confirm the presence of international ST206 and ST354 carrying mcr-1.1 genes and that the IncX4 plasmids have been key vectors contributing to the endemic status of mcr-1.1-positive polymyxin-resistant E. coli in Brazil. Also, we described the first known clinical isolate with the mrc1.1 gene in Santa Catarina state, Brazil, showing that plasmid-mediated polymyxin resistance has been affecting humans earlier than has been known so far.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.